TCGA-A7-A26J-01B-02R-A277-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 21
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.380
- INTERFERON_ALPHA_RESPONSE+0.350
- INTERFERON_GAMMA_RESPONSE+0.250
- MITOTIC_SPINDLE+0.200
- WNT_BETA_CATENIN_SIGNALING+0.170
- TGF_BETA_SIGNALING+0.110
- INFLAMMATORY_RESPONSE+0.080
- PROTEIN_SECRETION+0.060
- ANDROGEN_RESPONSE+0.050
- SPERMATOGENESIS+0.020
Top 10 suppressed
- MYC_TARGETS_V2-0.650
- OXIDATIVE_PHOSPHORYLATION-0.560
- MYC_TARGETS_V1-0.520
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.480
- CHOLESTEROL_HOMEOSTASIS-0.430
- MTORC1_SIGNALING-0.430
- UV_RESPONSE_UP-0.430
- ADIPOGENESIS-0.410
- DNA_REPAIR-0.410
- FATTY_ACID_METABOLISM-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AC-A3OD-01B-06R-A22O-07 | — | D | 0.937 |
| 2 | TCGA-AC-A3OD-01A-11R-A21T-07 | — | D | 0.905 |
| 3 | TCGA-A7-A26E-01B-06R-A277-07 | — | D | 0.884 |
| 4 | AUR-AER7-TTP1-A-1-0-R-A741-41 | — | D | 0.869 |
| 5 | TCGA-44-2665-01B-06R-A277-07 | — | cohortMD2 | 0.868 |
| 6 | bae6fdb5-9df3-433c-9a4c-e5c159a62bc6 | — | — | 0.860 |
| 7 | TCGA-A7-A13E-01B-06R-A277-07 | — | D | 0.859 |
| 8 | TCGA-E2-A15I-01A-21R-A137-07 | — | B | 0.853 |
| 9 | TCGA-AC-A3QQ-01B-06R-A22O-07 | — | D | 0.845 |
| 10 | b8135e73-31c3-49af-b4da-a7ed5f28d68a | — | — | 0.844 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.380 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.350 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.250 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.110 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.080 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.060 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.050 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.020 | Inavolisib | — uncovered |